BTC-1.67%
Market Analysis
Starboard Value Reportedly Acquires $1B Stake in Pfizer as Stock Lags S&P 500 by 46%
Activist investor Starboard Value has reportedly taken a $1 billion stake in pharmaceutical giant Pfizer.
Editorial disclosureRead more
All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.
Activist investor Starboard Value has reportedly acquired a significant stake in pharmaceutical giant Pfizer (NYSE: PFE), potentially signaling major changes for the drugmaker. The news has already impacted Pfizer’s stock price and raised questions about the company’s future direction.
Activist Investor Takes Significant Stake in Pfizer
Starboard Value, an activist investment fund run by Jeff Smith, has built a roughly $1 billion position in Pfizer. The fund, known for its technology-sector focus and recent campaigns at companies like Autodesk (NASDAQ: ADSK) and Salesforce (NYSE: CRM), is reportedly seeking assistance from former Pfizer CEO Ian Read and ex-finance chief Frank D’Amelio.
While Starboard’s exact plans remain undisclosed, the move suggests a push for significant changes in Pfizer’s strategy and operations.
The activist investor’s involvement implies potential pressure on current CEO Albert Bourla’s leadership and scrutiny of Pfizer’s recent acquisition strategy and cost structure. Analysts speculate that Starboard may advocate for a return to a more disciplined approach to expenses and a renewed focus on novel drug development.
Pfizer Stock Sees Gains in Premarket Trading
Pfizer’s stock has shown an immediate reaction to the news, with pre-market trading on Monday, October 7, showing a 3.04% increase to $29.45 per share as of 7:53 AM EDT (at the time of writing).
The company’s financial metrics paint a mixed picture: while Pfizer boasts a trailing twelve-month revenue of $55.17 billion, it also reports a negative EPS of $0.46 and a net income loss of $2.59 billion for the same period.
Despite these challenges, Pfizer maintains a strong cash position of $7.1 billion and offers an attractive forward dividend yield of 5.74%. The company’s stock performance has lagged behind the S&P 500 index, with a one-year return of -10.72% compared to the index’s 35.98% gain.
Analyst recommendations for Pfizer stock remain mixed, ranging from “Neutral” to “Overweight,” with an average price target of $33.34.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
Tim Fries
Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.
